CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead

Abstract

The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including RB1/PTEN/P53-deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that lie ahead in bringing CDC25 inhibitors to the clinic.

Keywords

• triple negative breast cancer
• therapy
• cdc25 inhibitors
• rb1
• p53
• pten